Joaquim Mullol

Grup de recerca

Immunoal·lèrgia respiratòria clínica i experimental (IRCE) Group leader (R4)

jmullol@clinic.cat 0000-0003-3463-5007

Segueix-lo/a a:

El perfil de ResearchGate de Joaquim . Aquest enllaç s'obre en una nova pestanya.

Publicacions destacades

EUFOREA Consensus on Biologics for CRSwNP with or without asthma

Autors:
Fokkens WJ; Lund V; Bachert C; Mullol J; Bjermer L;

(...)

Mariën G; Pugin B; Senior B; Seys SF; Hellings PW .

Referència: Allergy 2019.
Olfactory Training Prevents Olfactory Dysfunction Induced by Bulbar Excitotoxic Lesions: Role of Neurogenesis and Dopaminergic Interneurons

Autors:
Marin C; Laxe S; Langdon C; Alobid I; Berenguer J;

Fuentes M; Bernabeu M; Mullol J .

Referència: Molecular Neurobiology 2019.
Recovery of Olfactory Function After Excitotoxic Lesion of the Olfactory Bulbs Is Associated with Increases in Bulbar SIRT1 and SIRT4 Expressions

Autors:
Marin C; Langdon C; Alobid I; Fuentes M; Bonastre M;

Mullol J.

Referència: Molecular Neurobiology 2019.
Olfactory training in posttraumatic smell impairment: mild improvement in threshold performances - results from a randomized controlled trial.

Autors:
Langdon C; Lehrer E; Berenguer J; Laxe S; Alobid I;

Quintó L; Mariño-Sánchez F; Bernabeu M; Marin C; Mullol J .

Referència: Journal Of Neurotrauma 2018.
Smell loss is associated with severe and uncontrolled disease in children and adolescents with persistent allergic rhinitis.

Autors:
Mariño-Sanchez F; Valls-Mateus M; Haag O; Alobid I; Bousquet J;

Mullol J .

Referència: Journal Of Allergy And Clinical Immunology 2018.
Nasal obstructive disorders impair health-related quality of life in adolescents with persistent allergic rhinitis: a real-life study.

Autors:
Valls-Mateus M; Marino-Sanchez F; Ruiz-Echevarría K; Cardenas-Escalante P; Jiménez-Feijoo R;

(...)

Giner-Muñoz MT; Haag O; Alobid I; Plaza Martin AM; Mullol J .

Referència: Pediatric Allergy And Immunology 2017.
Position paper on olfactory dysfunction

Autors:
Hummel T; Whitcroft KL; Andrews P; Altundag A; Cinghi C;

(...)

Soler G; Stjärne P; Stuck BA; Vodicka J; Welge-Luessen A.

Referència: Rhinology. Supplement 2017.
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

Autors:
Bachert C; Mannent L; Naclerio RM; Mullol J; Ferguson BJ;

(...)

Radin A; Gandhi NA; Stahl N; Yancopoulos GD; Sutherland ER .

Referència: Jama-Journal Of The American Medical Association 2016.
Furthering the understanding of olfaction, prevalence of loss of smell and risk factors: a population-based survey (OLFACAT study)

Autors:
Mullol, Joaquim; Alobid, Isam; Marino-Sanchez, Franklin; Quinto, Llorenc; de Haro, Josep;

Bernal-Sprekelsen, Manuel; Valero, Antonio; Picado, Cesar; Marin, Concepcio.

Referència: Bmj Open 2012.
EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists

Autors:
Fokkens, Wytske J; Lund, Valerie J; Mullol, Joachim; Bachert, Claus; Alobid, Isam;

(...)

Thomas, Mike; Toskala, Elina; Voegels, Richard; Wang, de Yun; Wormald, Peter John.

Referència: Rhinology 2012.

Projectes destacats

Papel de los microRNA en la modulación in vitro de la diferenciación mucociliar e inflamación del epitelio nasosinusal en la poliposis nasal

Investigador/a principal: Joaquim Mullol I Miret

Finançador: Fondo de Investigación Sanitaria (FIS) Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo

Codi: PI18-00469

Durada: 01/01/2019 - 31/12/2021
Expression of Rupatadine on PAF-induced inflammation in blood eosinophils and epithelial cells from nasal polyps and healthy nasal mucosa (RINOPAF-2 Study).

Investigador/a principal: Joaquim Mullol I Miret

Finançador: URIACH S.A

Codi: RINOPAF-02-2018

Durada: 01/01/2019 - 31/12/2021
Función reguladora de los microRNA sobre los genes diana involucrados en la diferenciación epitelial de la mucosa nasosinusal en la poliposis nasal.

Investigador/a principal: Joaquim Mullol I Miret

Finançador: Fondo de Investigación Sanitaria (FIS) Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo

Codi: PI15-00046

Durada: 01/01/2016 - 31/12/2019
Estudio de los mecanismos por los cuales el Omalizumab es capaz de mejorar el asma persistente asociada a la Enfermedad Respiratoria Exacerbada por AINES (EREA)

Investigador/a principal: Irina Bobolea

Finançador: SEPAR

Codi: SEPAR'18

Durada: 01/01/2019 - 31/12/2021
Study of the antiinflammatory mechanisms of action of MP29-02, compared to fluticasone propionate and azelastine alone, in healthy and inflamed human ansal mucosa: regulation on anti- and pro-inflammatory genes and GR.

Investigador/a principal: Joaquim Mullol I Miret

Finançador: MEDA Pharma

Codi: DYMECOS II

Durada: 01/01/2016 - 31/12/2019

Joaquim Mullol

Grup de recerca

Publicacions destacades

Projectes destacats

Papel de los microRNA en la modulación in vitro de la diferenciación mucociliar e inflamación del epitelio nasosinusal en la poliposis nasal

Expression of Rupatadine on PAF-induced inflammation in blood eosinophils and epithelial cells from nasal polyps and healthy nasal mucosa (RINOPAF-2 Study).

Función reguladora de los microRNA sobre los genes diana involucrados en la diferenciación epitelial de la mucosa nasosinusal en la poliposis nasal.

Estudio de los mecanismos por los cuales el Omalizumab es capaz de mejorar el asma persistente asociada a la Enfermedad Respiratoria Exacerbada por AINES (EREA)

Study of the antiinflammatory mechanisms of action of MP29-02, compared to fluticasone propionate and azelastine alone, in healthy and inflamed human ansal mucosa: regulation on anti- and pro-inflammatory genes and GR.

Subscriu-te a la Newsletter del Clínic